Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
Stopped Decision based on the low enrollment mainly due to high efficacy drugs available in 1st line ALK-positive NSCLC (eg alectinib), not due to any safety concerns
Conditions
- ALK-positive Advanced NSCLC
Interventions
- DRUG: Crizotinib
- DRUG: Pembrolizumab
Sponsor
Pfizer
Collaborators